Your browser doesn't support javascript.
loading
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin.
Alvarez, Guillermo Cabrera; Gómez-Galicia, Diana; Rodríguez-Fragoso, Lourdes; Marina, Vicente Madrid; Dorantes, Luis Cañedo; Sánchez-Alemán, Miguel; Méndez-Sánchez, Nahum; Esparza, Jorge Reyes.
Afiliación
  • Alvarez GC; Departamento de Gastroenterología y Hepatología, Hospital General Regional UMF No. 1, Instituto Mexicano del Seguro Social. Cuernavaca, Morelos, México.
Ann Hepatol ; 10(4): 458-68, 2011.
Article en En | MEDLINE | ID: mdl-21911886
BACKGROUND: Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV. OBJECTIVE: The aim of this pilot clinical trial was to assess the efficacy, tolerability and safety of Danazol in thrombocytopenia associated with PEG-INF and ribavirin treatment in patients with HCV. MATERIAL AND METHODS: We included patients whose platelets were < 90,000/mm³ and who were undergoing antiviral treatment. Danazol (300-600 mg/day) was administered during and until the end of antiviral therapy [7.6 months (2 to 11 months)]. The monitoring was performed through platelet analysis and liver function tests. A viral load test was done at the beginning and end of treatment. Fortynine patients receiving a combined therapy of PEG-INF, ribavirin and Danazol increased their platelet levels to 121,081/mm³ (46,000-216,000/mm³); 10.6% of patients gained > 100,000 platelets/mm³, and 71% of patients maintained their initial platelet levels. Sustained viral response (SVR) was achieved in 63% of patients. SVR rates were high in patients with genotype non 1 (78.7%) and decreased in patients with genotype 1 (60.1%). The increase in platelet levels was associated to an increase in fibrinogen levels and a decrease in the activity of ALT. By contrast, patients without SVR presented a delayed response to increased platelet levels and showed no significant improvement in liver function when they received Danazol. CONCLUSION: Danazol can be used along with PEG-INF and ribavirin to treat thrombocytopenia in patients with HCV.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Polietilenglicoles / Ribavirina / Trombocitopenia / Interferón-alfa / Hepatitis C Crónica / Danazol Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Mexico Idioma: En Revista: Ann Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2011 Tipo del documento: Article Pais de publicación: México
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Polietilenglicoles / Ribavirina / Trombocitopenia / Interferón-alfa / Hepatitis C Crónica / Danazol Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Mexico Idioma: En Revista: Ann Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2011 Tipo del documento: Article Pais de publicación: México